Coronavirus guidance by organisation
Midlands and Lancashire Commissioning Support Unit
The list of resources will be updated as new material becomes available so please check back regularly for updates.
This page groups the resources by the organisation that issued it. The same list of resources is also available grouped by subject matter.
Regional and national
Professional and regulatory
Independent and patient advocacy
Regional and national
Midlands and Lancashire Commissioning Support Unit
- Anticoagulation in cancer (RDTC guidance adopted by MLCSU)
- Asthma and COPD- oral steroid or antibiotic 'rescue packs' and extra steroid inhalers (RDTC guidance adopted by MLCSU)
- Depot antipsychotic injections: Administration during COVID-19 in stable adult patients
- Disease modifying drugs: monitoring guidance
- Electronic Repeat Dispensing (Wessex Academic Health Science Network guidance adopted by MLCSU )
- Lithium for stable adult patients: monitoring guidance
- Management of patients currently on warfarin during COVID-19 (SPS guidance adopted by MLCSU)
- Monitoring direct acting oral anticoagulants (DOACs) during the COVID-19 pandemic (RDTC guidance adopted by MLCSU)
- Prescribing for Asthma and COPD guidance (RDTC guidance adopted by MLCSU)
- Prescribing in diabetes (RDTC guidance adopted by MLCSU)
- Testosterone injection - administration and monitoring guidance (MLCSU)
- Vitamin B12 replacement
- Vitamin D and infection risk (RDTC guidance adopted by MLCSU)
GOV.UK
- Coronavirus (COVID-19): admission and care of people in care homes
- Coronavirus (COVID-19): support for care homes (DHSC)
- Our plan to rebuild: The UK Government’s COVID-19 recovery strategy
- The Misuse of Drugs (Coronavirus) (Amendments Relating to the Supply of Controlled Drugs During a Pandemic etc.) Regulations 2020
Medicines and Healthcare products Regulatory Agency
- COVID-19 Therapeutic Alert: Dexamethasone in the treatment of COVID-19
- Guidance for Manufacturers Specials licence holders on ‘packing down’ medicines during the coronavirus (COVID-19) outbreak
- MHRA guidance on coronavirus (COVID-19)
- MHRA regulatory flexibilities resulting from coronavirus (COVID-19)
- Coronavirus (COVID-19) and high blood pressure medication
- Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment
- Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19)
Managing symptoms and complications
- Acute kidney injury in hospital - NG175
- Acute myocardial injury - NG171
- Antibiotics for pneumonia in adults in hospital - NG173
- Critical care in adults - NG159
- Managing suspected or confirmed pneumonia in adults in the community - NG165
- Managing symptoms (including at the end of life) in the community - NG163
- Managing the long-term effects of COVID-19 - NG188
- Reducing the risk of venous thromboembolism in over 16s with COVID-19 - NG186
- Vitamin D - NG187.
Managing conditions that increase risk
- Children and young people who are immunocompromised - NG174
- Chronic kidney disease - NG176
- Community-based care of patients with chronic obstructive pulmonary disease (COPD) - NG168
- Cystic fibrosis - NG170
- Dermatological conditions treated with drugs affecting the immune response - NG169
- Gastrointestinal and liver conditions treated with drugs affecting the immune response - NG172
- Interstitial lung disease - NG177
- Rheumatological autoimmune, inflammatory and metabolic bone disorders - NG167
- Severe asthma - NG166.
Providing services during the pandemic
Rapid evidence summaries
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES23.
- Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis - ES26
- Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 - ES24
- Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES25
- Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 - ES27
- Sarilumab for COVID-19 - ES34
- Tocilizumab for COVID-19 - ES33.
Medtech innovation briefings
- CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic - MIB219
- Cytokine adsorption devices for treating respiratory failure in people with COVID-19 - MIB217
- FebriDx for C-reactive protein and myxovirus resistance protein A testing - MIB224
- Lifelight First for monitoring vital signs - MIB213
- myCOPD for self-management of chronic obstructive pulmonary disease - MIB214.
NHS England and NHS Improvement
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19
- Advice on how to establish a remote ‘total triage’ model in general practice using online consultations
- Advice regarding NHS volunteers relating to COVID-19
- After-care needs of inpatients recovering from COVID-19
- Coronavirus (COVID-19): reuse of medicines in a care home or hospice
- Coronavirus guidance for clinicians and NHS managers
- COVID-19 response: Identifying a clinical lead for all care homes
- Clinical guidelines for children and young people with palliative care needs in all care settings during the COVID19 pandemic
- Electronic Repeat Dispensing: Letter from Dr Nikita Kanani, Dr Keith Ridge and Ed waller: 4 June 2020
- Information for GPs advising both shielding and non shielding patients on support available during the COVID 19 pandemic
- Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
- Management of patients with musculoskeletal and rheumatic conditions on corticosteroids
- Managing coronavirus (COVID-19) in general practice (SOP)
- Primary care and community health support care home residents
- Principles of safe video consulting in general practice during COVID-19
- Revised arrangements for NHS contracting and payment during the COVID-19 pandemic
- Resumption of dental services in England
- Second phase of NHS response to COVID-19: Letter from Sir Simon Stevens and Amanda Pritchard
- Specialty guides
- Type 1 and Type 2 diabetes and COVID-19 related mortality in England
NHS North West
- Bulk Prescribing for Care Homes: A Guide for Care Home Teams
- Care Home and Hospice Homely Remedy Guidance during COVID-19
- Care homes’ safe access and use of medicines: guidance, templates and flowcharts
- Care home support - locality template
- COVID-19 End of Life Anticipatory Care Plan – supporting information for Medicines Optimisation Teams
- COVID-19 Primary Care Symptom Management Drug Therapy Options
- COVID-19 Supporting Guidance for prescribers working within COVID hubs and Medicine Conveyance with GP bags
- Medication Acquisition Guidance during COVID-19 for Care Homes with Nursing and Hospices
- Medication Acquisition Guidance during COVID-19 for Care Homes without Nursing
- Organisational Prescribing Code and EPS Guide for Primary Care
- Prescribers obtaining COVID-19 medicines for symptom control and treatment: guidance and templates
- Reuse of Medicines in Northwest Care Homes during the COVID-19 Pandemic: Guidance and Resources
- Risks Assessment and Considerations – for setting up COVID-19 Hubs